We have located links that may give you full text access.
Reinterventions and Sac Dynamics after Fenestrated Endovascular Aortic Repair with Physician-Modified Endografts for Index Aneurysm Repair and Following Proximal Failure of Prior Endovascular Aortic Repair.
Journal of Vascular Surgery 2024 January 6
OBJECTIVE: The high frequency of reinterventions after Fenestrated Endovascular Aortic Repair (FEVAR) with Physician Modified Endografts (PMEGs) has been well-studied. However, the impact of prior EVAR on reinterventions and sac behavior following these procedures remains unknown. We analyzed 3-year rates of reinterventions and sac dynamics following PMEG for index aneurysm repair compared with PMEG for prior EVAR with loss of proximal seal.
METHODS: We performed a retrospective analysis of 122 consecutive FEVARs with PMEGs at a tertiary care center submitted to the FDA in support of an Investigational Device Exemption trial. We excluded patients with aortic dissection (5), type I-III thoracoabdominal aneurysms (13), non-elective procedures (4), and prior aortic surgery other than EVAR (8), for a final cohort of 92 patients. Patients were divided into those who underwent PMEG for index aneurysm repair (primary-FEVAR) and those who underwent PMEG for rescue of prior EVAR with loss of proximal seal (secondary-FEVAR). The primary outcomes were freedom-from reintervention and sac dynamics (regression as ≥5mm decrease, expansion as ≥5mm increase, and stability as <5mm increase or decrease) at 3-years. Secondary outcomes were perioperative mortality and 3-year survival.
RESULTS: Of the 92 patients included, 56 (61%) underwent primary-FEVAR and 36 (39%) underwent secondary-FEVAR. Secondary-FEVAR patients were older (78 years [IQR 74.5-83.5] vs 73 years [69-78.5], p<0.001), more frequently male (86% vs 68%, p=.048), and had larger aneurysms (72.5mm [65.5-81] vs 59mm [55-65], p<0.001). Perioperative mortality was 1.8% for primary-FEVAR and 2.7% for secondary-FEVAR (p=0.75). At 3-years, overall survival was 84% for index-FEVAR and 71% for secondary-FEVAR (p=0.086). Freedom-from reintervention was significantly higher for index-FEVAR than secondary-FEVAR, specifically 82% versus 38% at 3-years (p<0.001). Primary-FEVAR also had more desirable sac dynamics relative to secondary-FEVAR at 3-years (primary: 54% stable, 46% regressed, 0% expanded vs secondary: 33% stable, 28% regressed, and 39% expanded, p=.038).
CONCLUSIONS: FEVAR for primary aortic repair and FEVAR for rescue of prior EVAR with loss of proximal seal are two distinct entities. Following primary-FEVAR, less than a quarter of patients have undergone reintervention at 3 years and sac expansion was not seen in our cohort. Comparatively, 3 years after secondary-FEVAR, over half of patients have undergone reintervention and over a third have had ongoing sac expansion. Vigilant surveillance and a low threshold for further interventions are crucial following secondary-FEVAR.
METHODS: We performed a retrospective analysis of 122 consecutive FEVARs with PMEGs at a tertiary care center submitted to the FDA in support of an Investigational Device Exemption trial. We excluded patients with aortic dissection (5), type I-III thoracoabdominal aneurysms (13), non-elective procedures (4), and prior aortic surgery other than EVAR (8), for a final cohort of 92 patients. Patients were divided into those who underwent PMEG for index aneurysm repair (primary-FEVAR) and those who underwent PMEG for rescue of prior EVAR with loss of proximal seal (secondary-FEVAR). The primary outcomes were freedom-from reintervention and sac dynamics (regression as ≥5mm decrease, expansion as ≥5mm increase, and stability as <5mm increase or decrease) at 3-years. Secondary outcomes were perioperative mortality and 3-year survival.
RESULTS: Of the 92 patients included, 56 (61%) underwent primary-FEVAR and 36 (39%) underwent secondary-FEVAR. Secondary-FEVAR patients were older (78 years [IQR 74.5-83.5] vs 73 years [69-78.5], p<0.001), more frequently male (86% vs 68%, p=.048), and had larger aneurysms (72.5mm [65.5-81] vs 59mm [55-65], p<0.001). Perioperative mortality was 1.8% for primary-FEVAR and 2.7% for secondary-FEVAR (p=0.75). At 3-years, overall survival was 84% for index-FEVAR and 71% for secondary-FEVAR (p=0.086). Freedom-from reintervention was significantly higher for index-FEVAR than secondary-FEVAR, specifically 82% versus 38% at 3-years (p<0.001). Primary-FEVAR also had more desirable sac dynamics relative to secondary-FEVAR at 3-years (primary: 54% stable, 46% regressed, 0% expanded vs secondary: 33% stable, 28% regressed, and 39% expanded, p=.038).
CONCLUSIONS: FEVAR for primary aortic repair and FEVAR for rescue of prior EVAR with loss of proximal seal are two distinct entities. Following primary-FEVAR, less than a quarter of patients have undergone reintervention at 3 years and sac expansion was not seen in our cohort. Comparatively, 3 years after secondary-FEVAR, over half of patients have undergone reintervention and over a third have had ongoing sac expansion. Vigilant surveillance and a low threshold for further interventions are crucial following secondary-FEVAR.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app